New antibody shot shows promise for HIV control and prevention
NCT ID NCT05890963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on regular medication. The goal is to see if the antibody is safe and can lower the amount of virus in the blood. Results will help design future studies for both HIV treatment and prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute for Medical Research-Mbeya Medical Resarch Center
Mbeya, Tanzania
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo